Research
Hormonal
Gut hormones (GLP-1, GIP, CCK, PYY, OXM) regulate food intake and energy homeostasis by acting on the hypothalamus and brainstem via direct circulation or vagus nerve signaling, while ghrelin stimulates appetite.
Understanding that gut hormones like GLP-1 and GIP signal satiety to the brain helps explain why medications mimicking these hormones (like semaglutide and tirzepatide) are effective for weight loss. Conversely, ghrelin signals hunger. This biological basis supports the use of drugs that target these pathways.
GoodSupportsHIGH confidence
Gut hormones are key metabolic signals in gut-brain communication and act as short-term regulators of food intake [52,53]. GLP-1, GIP, CCK, PYY, and oxyntomodulin (OXM) are secreted in response to nutrients and induce satiety, whereas ghrelin is secreted in anticipation of nutrients and stimulates the appetite.
Why this rating
Based on a comprehensive review of multiple studies and mechanisms.
Source
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh et al. · International Journal of Molecular Sciences · 2023
DOI 10.3390/ijms24043384
narrative_reviewCited 43×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater weight loss (up to 20.9%) compared to selective GLP-1 receptor agonists (e.g., semaglutide) by activating both GIP and GLP-1 signaling pathways in the brain and peripheral tissues.Strong
- Semaglutide 2.4 mg weekly produces significant weight loss (approx. 14.9%) in overweight and obese adults without diabetes, significantly outperforming placebo and older GLP-1 agonists like liraglutide.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →